ImmunoGenesis

ImmunoGenesis to Present Pre-Clinical Data from Lead Program at Society for Immunotherapy of Cancer Conference See more here

ImmunoGenesis Appoints Oncology Research Veteran to Lead Immuno-Oncology Clinical Development Targeting Immune-Excluded, “Cold” Cancers Clinical trials for ImmunoGenesis drug candidates to initiate in 2022 See more here

Data from ImmunoGenesis' Lead Programs Presented in Six Posters at Society for Immunotherapy of Cancer (SITC) Conference See more here

ImmunoGenesis Announces Positive Preclinical Glioblastoma and Pancreatic Cancer Data for STimulator of INterferon Genes (STING) Agonist Published in Two Scientific Journals  STING agonist can induce innate immune responses that allow the immune system to fight otherwise immunologically resistant cancers  Phase 1 canine glioblastoma veterinary trial data show the promise of…

ImmunoGenesis Expands R&D, Clinical and Business Development Teams and Opens Research Laboratory Clinical and CMC hires to ready initiation of multiple immuno-oncology clinical programs in 2022  Proven business development expertise key to executing global clinical development strategy  R&D hires and lab opening to facilitate critical translational research See more here

ImmunoGenesis: Acquisition Strengthens “Cold” Tumor Targeting Pipeline ImmunoGenesis acquires rights to evofosfamide; Phase 2 clinical testing in combination with checkpoint blockade is planned for 2021. Evofosfamide is the only known reducer of solid tumor hypoxia, a driver of therapeutic resistance in immunologically “cold” tumors such as pancreatic & prostate cancer. …